The Gross Law Firm has announced a class action lawsuit against Neumora Therapeutics (NMRA) alleging the company made false or misleading statements about its Phase Two clinical trials for Navacaprant, its therapeutic candidate for Major Depressive Disorder (MDD). The lawsuit claims Neumora manipulated trial inclusion criteria and statistical analysis to show potential efficacy, with shareholders who purchased stock from September 15, 2023, eligible to participate.